|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
An Ancillary Study of the STAMPEDE Trial Assessing the Clinical Qualification of Transcriptome Signatures for Advanced Prostate Cancer Starting ADT +/- Abiraterone Acetate and Prednisolone
|
Gerhardt Attard, MD, Ph.D., FRCP
Gerhardt Attard joins Ashley Ross in discussing an ancillary study of the STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone.
|
|
|
|
|
|
|
|
|
|
|
|
Rationale for the Use of Decipher RP Genomic Classifier to Inform Treatment
|
Ashley Ross, MD, Ph.D.
Alicia Morgans and Ashley Ross discuss the Decipher RP genomic classifier for prostatectomy specimens, and how to integrate these tests into clinical practice. Decipher is a genomic classifier that looks at the whole genome and expression patterns on that genome.
|
|
|
|
|
|
|
|
|
|
|
| How Can Treatment Be Individualized By Using Genomic Classifiers? APCCC 2022 Presentation |
| Felix Feng, MD |
| At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Felix Feng presents how treatment for prostate cancer can be individualized by using genomic classifiers. |
|
|
|
|
|
|
|
|
|
|
|
| Clinical Qualification of Transcriptome Signatures for Advanced Prostate Cancer Starting ADT with or Without Abiraterone Acetate and Prednisolone: An Ancillary Study of the STAMPEDE AAP Trial
|
| Marina Parry, BSc, Ph.D.
|
| Marina Parry discusses an ancillary study of the STAMPEDE trial assessing clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone. The addition of abiraterone acetate and prednisolone to ADT is standard of care for advanced prostate cancer (metastatic, M1 and high-risk non-metastatic, M0).
|
|
|
|
|
|
| Differential Treatment Response with Nodal Metastases in mHSPC and the Evaluation of Nodal Burden as a Prognostic Biomarker -Ancillary Studies of the Docetaxel and Abiraterone Acetate and Prednisolone Phase III Trials from STAMPEDE
|
| Áine M Haran, BSc (Hons), BMBS, MRCS
|
| Áine Haran discusses ancillary studies of the docetaxel and abiraterone acetate and prednisolone phase III trials from STAMPEDE, specifically differential treatment response with nodal metastases in mHSPC and the evaluation of nodal burden as a prognostic biomarker. A better selection of patients for the addition of docetaxel in mHSPC is required. Previous work has suggested that increased disease burden correlates with worse outcomes, but nodal metastases have not been considered in metastatic volume definitions in mHSPC.
|
|
|
|
|
|
| Transcriptome-Based Prognostic and Predictive Biomarker Analysis of ENACT: A Randomized Controlled Trial of Enzalutamide (ENZA) in Men Undergoing Active Surveillance (AS)
|
| Ashley Ross, MD, Ph.D.
|
| Ashley Ross presents a transcriptome-based assessment of prognostic and predictive biomarkers among patients in the ENACT trial of enzalutamide in patients undergoing active surveillance for prostate cancer. Active surveillance is widely used and recommended for men with low- or intermediate-risk prostate cancer in order to avoid adverse treatment effects.
|
|
|
|
|
|
|
|
|
|
|
| Additional Insights from the STAMPEDE Trial Platform |
| Elena Castro, MD |
| Elena Castro discusses two key studies from the STAMPEDE trial platform, including “Comparison of abiraterone acetate and prednisolone or combination enzalutamide + abiraterone acetate and prednisolone for mHSPC starting ADT: OS results of 2 randomized Phase III trials from the STAMPEDE protocol” presented by Dr. Gerhardt Attard, and “Clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone: an ancillary study of the STAMPEDE AAP trial” presented by Dr. Marina Parry. |
|
|
|
|
|
| Biomarker-Directed Therapy in Black and White Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
| Clara Hwang, MD |
| Black men in the United States have higher incidence of prostate cancer and, in broad collections of data, worse outcomes. These disparities are subject to study to determine their social and biological contributors. A paucity of molecular data for Black men with prostate cancer has limited investigation to date. In fact, Black men have been under-represented in large-scale molecular prostate cancer surveys. |
|
|
|
|
|
| How Can Treatment Be Individualized By Using Genomic Classifiers? |
| Felix Feng, MD |
| The 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting included a session on biochemical recurrence, and a presentation by Dr. Felix Feng discussing how treatment can be individualized by using genomic classifiers. Dr. Feng started by highlighting that genomic biomarkers are included in certain treatment guidelines for the management of PSA recurrences. In the NCCN guidelines, the Decipher molecular assay is recommended for risk stratification among men with PSA persistence or recurrence. |
|
|
|
|
|
|
